why choose us

First received: April 12, 2023

Clinical Trial: Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Cancer

Study Type: INTERVENTIONAL


Official Title: A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

Brief Summary: This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Read more